Radioimmunoassay is now universally used for the assay of all biologically active gastrointestinal peptides. There are, however, no simple sensitive bioassays for any gastrointestinal peptide except cholecystokinin.
Cholecystokinin (CCK) acts predominantly on the gall bladder to produce contraction and on the pancreas to produce pancreatic secretion. The biological activity of cholecystokinin is consequently expressed in two quite different units. The first is the Crick Harper Raper unit (CHRU), which is a measure ofpancreatic secretion rate in an intact anaesthetised cat. The second unit is the Ivy dog unit (IDU). This is a measure of the rise in gall bladder pressure produced in an intact anaesthetised dog. Both of these units are assayed in vivo and the assays are difficult, tedious, and expensive.
There are two commercially available preparations of CCK and the activity of each is expressed in different units. The Boots preparation is standardised in Crick Harper Raper units, the GIH Laboratories preparation is standardised in Ivy dog units.
An in vitro bioassay of CCK has recently been describedl-3 using isolated strips of rabbit gall bladder which has a clear advantage over the previously in vivo bioassays. However, the authors claimed that this simple bioassay was not influenced by variations in tissue sensitivity. Our
Received for publication 28 July 1981 experience is quite contrary to this view. An identical dose ofpure cholecystokinin administered to the preparation repeatedly over several hours has given widely different magnitudes of response by the tissue, sometimes changing by a factor of four or five. This change in sensitivity of the preparation would often occur suddenly after several hours of reasonably stable responsiveness. These biological variations in tissue sensitivity are well recognised and occur in all biological assay systems. Indeed, it would be surprising if rabbit gall bladder were spared this. Because of this biological variation in tissue response, a result for an unknown sample can not simply be read from a dose response curve constructed from the response to standard concentrations administered earlier in the experimental period, because the tissue sensitivity frequently changes between these two points in time. This problem is obviated by the standard technique of a four point assay-two concentrations of unknown assayed and two concentrations of standard assayed in a fixed time interval and then mathematically validated to ensure that no significant variation occurred during that time interval.
We have studied the validity, precision, and specificity of such an in vitro bioassay for cholecystokinin. (GIH CCK) . The concentration of the standard was chosen so that the height of the contractions produced was approximately the same as that produced by the unknowns. The dose interval between the high and low concentration of standard and the high and low concentration of unknown were identical.
The mean results could be expressed diagramatically as shown (Figure) , and the relative potency of the unknown with respect to the standard would be given by the horizontal distance between the two lines obtained, if the lines are parallel.
The validity of each assay was checked statistically by the methods recommended oy Gaddum. This assumes a molecular weight of 3883 for cholecystokinin. One IDU of GIH CCK was contained in 333 ng or 86 pM.
SENSITIVITY
The assays were consistently invalid at CCK concentrations below 2.5 m IDU/ml.
Discussion
We have found that the sensitivity of isolated rabbit gall bladder strips to superfused cholecystokinin is not constant as previously suggested.2 In contrast, a marked variation in tissue sensitivity has been consistently observed during the process of bioassay, which was a major source of error. We, therefore, consider previous assays which have ignored this variability to be inadequate. The assays reported here have been individually validated mathematically by internationally accepted criteria.
The Ivy dog unit of CCK activity is defined as that amount of dry material which, dissolved in normal saline and injected intravenously during 10-15 seconds into an anaesthetised dog weighing approximately 15 kg, causes a more or less immediate rise in intra gall bladder pressure of 1 cm of bile. The Crick Harper Raper unit is that amount of activity which was present in 0. 1 mg of an arbitrarily chosen standard preparation of secretin prepared by the method of Harper and Raper (1943) .5 In the original description one unit produced an average flow of 1.2 ml of pancreatic juice in 12 minutes in an anaesthetised cat.
In our validated assay system, we find that these two units of CCK activity are fortuitously very similar, 1 CHRU being equivalent to 1.22 IDU.
It is well known that peptides which show a similar C-terminal pentapeptide sequence with cholecystokinin possess some cholecystokinetic properties. To assess the specificity of the assay we have studied some of these peptides.
The amphibian decapeptide caerulin was shown in this assay system to have 14 times the potency of cholecystokinin. The octapeptide of CCK was only slightly less potent than caerulin on a molar basis. This finding is in good agreement with Vagne and Grossman6 whose in vivo assay was well validated.
Cross-reactivity with gastrin often interferes with radioimmunoassays for CCK. In this bioassay the synthetic pentapeptide in the form ofpeptavlon was a very weak stimulant of gall bladder activity (0.0006 of the potency of CCK). Similarly, human synthetic (sulphated) gastrin (G 1, 17) did not produce dose dependent contractions except when grossly unphysiological concentrations (200-400 ng/ml) were used.
Secretin is believed to contaminate some commercial preparations of cholecystokinin. Pure synthetic secretin did not produce any contractions in this assay.
The assay, therefore, appears to be relatively specific for CCK when assayed as a superfusate in buffer. However, degradation ofthe CCK molecule liberating the octapeptide would clearly cause serious over-estimation of the CCK concentration by this method. This assay used purified CCK in a buffer solution. Cholecystokinin in serum will, of course, cause the rabbit gall bladder preparation to contract. However, when all cholecystokinin has been removed from serum before assay, the resulting serum will still cause a contraction. This has been called 'the blank effect'.3 There are, therefore, factors in serum other than cholecystokinin which cause gall bladder concentration and which have not yet been accurately identified. The parallel line assay assumes that there is a single substance-in this case, CCK-in the assay medium which produces a dose-related response. This is clearly not the case for serum where several different constituents-for example, histaminecan produce a cholecystokinin-like response-the 'blank effect'. Identification and elimination of these factors is essential before the concentration of CCK can be assayed biologically in serum.
The assay reported here is sensitive and relatively specific for CCK assayed in buffer but more work is required before the assay can be applied to serum. 
